Last reviewed · How we verify

NCT06913595

Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery

Active, enrolled Phase 1 Last updated 26 August 2025
What this trial tests

Phase 1 trial testing Direct Oral Anticoagulant. in Deep Venous Thrombosis in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
25 March 2024
Primary endpoint
25 October 2025
1 November 2025

Quick facts

Lead sponsorCairo University
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment100
Start date25 March 2024
Primary completion25 October 2025
Estimated completion1 November 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Eligibility, any sex, with Deep Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Deep Venous Thrombosis

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06913595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing